{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:5202",
      "entity_text" : "serotonin",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : [ {
      "in_model" : true,
      "identifier" : "pubchem:2913",
      "entity_text" : "Cyproheptadine",
      "entity_type" : "simple_chemical"
    }, {
      "in_model" : true,
      "identifier" : "uaz:UAZ04781",
      "entity_text" : "serotonin receptors",
      "entity_type" : "protein"
    } ],
    "hypothesis_information" : false
  },
  "verbose_text" : "Cyproheptadine, a 5HT 2A antagonist, has been reported to have variable success for treatment of serotonin syndrome in humans.12 Cyproheptadine binds serotonin receptors to competitively prevent serotonin molecules from binding to receptors.",
  "reading_complete" : "2020-08-03T16:10:34Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T16:09:12Z",
  "trigger" : "prevent",
  "evidence" : [ "Cyproheptadine binds serotonin receptors to competitively prevent serotonin" ],
  "pmc_id" : "6332764",
  "score" : 0
}